On target? Cardiovascular risk factor patterns in type 1 and type 2 diabetes: Real-world attainment of cardiovascular risk factor targets and use of medication

Cardiovascular Risk and Diseases

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Diabetes Obes Metab

Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J

doi: 10.1111/dom.70214

Cardiovascular Risk and Diseases

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial

J Am Heart Assoc

Zehra A, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ, Galindo RJ, Umpierrez GE, Ross JS, Brito JP, Montori VM, Borah BJ, Maron BA, Mickelson MM, McCoy RG

doi: 10.1161/JAHA.125.046238

Heart Failure

Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry

Eur J Heart Fail

Ferrannini G, Pol T, Ljungman C, Dahlström U, Merolla A, Lund LH

doi: 10.1093/ejhf/xuag249

Cardiovascular Risk and Diseases

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

JAMA Cardiol

Mulvagh SL, Inzucchi SE, Marx N, Poulter NR, Deanfield JE, Pop-Busui R, Emerson SS, Mann JFE, Engelmann MDM, Hovingh GK, Mandavya K, Davicevic-Elez Z, Jeppesen OK, Lorenzatti A, Oguz A, Mankovsky B, Deerochanawong C, Gorgojo-Martinez JJ, Ji L, Bain SC, McGuire DK, Buse JB, SOUL Study Group

doi: 10.1001/jamacardio.2026.0245

Cardiovascular Risk and Diseases

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Front Endocrinol (Lausanne)

Jiang W, Wang J, Li J, Li Y, Zhang Y, Xu J, Zhang J, Gao Z, Cheng J, Yang J, Chang B

doi: 10.3389/fendo.2026.1768816

COMMENTED

Heart, Artery and Coronary Diseases

Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

J Am Heart Assoc

Deng Y, Polley EC, Herrin J, Swarna KS, Kent DM, Ross JS, Maron BA, Mickelson MM, McCoy RG

doi: 10.1161/JAHA.124.040217

Myocardial Infarction

Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study

Lancet Diabetes Endocrinol

Smidtslund P, Harjutsalo V, Thorn V, Jansson Sigfrids F, Groop PH, Thorn LM, FinnDiane Study Group

doi: 10.1016/S2213-8587(25)00368-7

Cardiovascular Risk and Diseases

Longitudinal variability of lipoprotein(a) in youth-onset type 1 diabetes: implications for cardiovascular risk stratification

Cardiovasc Diabetol

Iafrate-Luterbacher F, Jimenez-Sanchez C, Anastasiadou ML, Prados J, Renström F, Brändle M, Bilz S, Schwitzgebel VM

doi: 10.1186/s12933-026-03252-7

Myocardial Infarction

Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study

Cardiovasc Diabetol

Tonnesen PT, Olesen KKW, Gyldenkerne C, Hansen MK, Stødkilde-Jørgensen N, Thrane PG, Andersen MH, Poulsen PL, Thomsen RW, Sattar N, Sørensen HT, Maeng M

doi: 10.1186/s12933-026-03085-4

Related content

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial

Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes: a contemporary, real-world analysis of the Swedish Heart Failure Registry

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial

Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk

Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study

Longitudinal variability of lipoprotein(a) in youth-onset type 1 diabetes: implications for cardiovascular risk stratification

Progression to type 2 diabetes among post-myocardial infarction patients with overweight or obesity: a real-world cohort study